Results 11 to 20 of about 5,478,695 (241)

CAR-NK cells: A promising cellular immunotherapy for cancer [PDF]

EBioMedicine, 2020
Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating ...
Guozhu Xie, Han Dong, Yong Liang, James Dongjoo Ham, Romee Rizwan, Jianzhu Chen   +5 more
doaj   +6 more sources

IPSC-derived CAR-NK cells for cancer immunotherapy

Biomedicine & Pharmacotherapy, 2023
Adoptive cell therapies (ACT) based on chimeric antigen receptor (CAR)-modified immune cells have made great progress with six CAR-T cell products approved by the U.S. FDA for hematological malignancies.
Guozhu Xie, Ryohichi Sugimura, Xin Dong, Dong, Xin, Xie, Guozhu, Lin, Xiaotong, Zishen Liu, Sun, Yao, Sugimura, Ryohichi, Xiaotong Lin, Liu, Zishen, Yao Sun   +11 more
core   +3 more sources

CAR-NK Cells in the Treatment of Solid Tumors [PDF]

International Journal of Molecular Sciences, 2021
CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy against hematological malignancies, the treatment is far from flawless ...
Ewa Wrona, Maciej Borowiec, Piotr Potemski   +2 more
core   +3 more sources

Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation [PDF]

Frontiers in Immunology
IntroductionCAR-T cell therapy is associated with life-threatening inflammatory toxicities, partly due to the activation and secretion of inflammatory cytokines by bystander myeloid cells (BMCs).
Supreet Khanal, Alan Baer, Md Kamal Hossain, Winston Colon-Moran, Santosh Panthi, Nirjal Bhattarai   +5 more
doaj   +2 more sources

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy

Frontiers in Immunology, 2022
Cancer immunotherapies utilize the capabilities of the immune system to efficiently target malignant cells. In recent years, chimeric antigen receptor (CAR) equipped T cells showed promising results against B cell lymphomas.
Katharina Eva Ruppel, Stephan Fricke, Ulrike Köhl, Ulrike Köhl, Ulrike Köhl, Dominik Schmiedel   +5 more
doaj   +2 more sources

Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models

Journal of Immunology Research, 2018
Adoptive chimeric antigen receptor-modified T or NK cells (CAR-T or CAR-NK) offer new options for cancer treatment. CAR-T therapy has achieved encouraging breakthroughs in the treatment of hematological malignancies.
Qing Zhang, Haixu Zhang, Jiage Ding, Hongyan Liu, Huizhong Li, Hailong Li, Mengmeng Lu, Yangna Miao, Liantao Li, Junnian Zheng   +9 more
doaj   +2 more sources

CAR-NK cells derived from cord blood originate mainly from CD56−CD7+CD34−HLA-DR−Lin− NK progenitor cells

Molecular Therapy: Methods & Clinical Development
Cord blood (CB)-derived chimeric antigen receptor (CAR)-natural killer (NK) cells targeting CD19 have been shown to be effective against B cell malignancies.
Tansri Wibowo, Yosuke Kogue, Shunya Ikeda, Moto Yaga, Mana Tachikawa, Makiko Suga, Shuhei Kida, Kumi Shibata, Kazuhito Tsutsumi, Hiraku Murakami, Yasutaka Ueda, Hisashi Kato, Kentaro Fukushima, Jiro Fujita, Tomoaki Ueda, Shinsuke Kusakabe, Akihisa Hino, Michiko Ichii, Chihaya Imai, Daisuke Okuzaki, Atsushi Kumanogoh, Naoki Hosen   +21 more
doaj   +2 more sources

The Advances and Challenges of CAR-NK Cells for Tumor Immunotherapy [PDF]

E3S Web of Conferences, 2019
Immunotherapies using chimeric antigen receptor (CAR)-T cells bring an encouraging vision to non-Hodgkin lymphoma patients who develop relapsed lymphoma or are unresponsive to standard chemotherapy, yet they also have limitations and drawbacks.
Ziyun A. Ye
core   +3 more sources

NK cells in renal cell carcinoma and its implications for CAR-NK therapy [PDF]

Frontiers in Cell and Developmental Biology
Renal cell carcinoma (RCC) is a malignancy that makes up 3% of adult cancers and 20%–30% of patients were diagnosed with metastatic RCC in the beginning, while the median overall survival (OS) of metastatic RCC systemic therapy ranges from 16 months to ...
Xinwei Li, Wen Xiao, Lei Liu, Yuzhong Ye, Yuanpeng Zhang, Xiaoping Zhang   +5 more
core   +4 more sources

RETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy [PDF]

Frontiers in Oncology, 2021
The tumor microenvironment (TME) is greatly multifaceted and immune escape is an imperative attribute of tumors fostering tumor progression and metastasis. Based on reports, the restricted achievement attained by T cell immunotherapy reflects the prominence of emerging other innovative immunotherapeutics, in particular, natural ...
Faroogh Marofi, Alaa S. Al-Awad, Heshu Sulaiman Rahman, Heshu Sulaiman Rahman, Alexander Markov, Alexander Markov, Walid Kamal Abdelbasset, Walid Kamal Abdelbasset, Yulianna Ivanovna Enina, Mahnaz Mahmoodi, Ali Hassanzadeh, Mahboubeh Yazdanifar, Max Stanley Chartrand, Mostafa Jarahian   +13 more
openaire   +3 more sources